Comparative structure-function studies with analogs of dynorphin-(1-13) and [Leu5]enkephalin

Area of Science:

• Pharmacology
• Neuroscience
• Biochemistry

Background:

• Opioid peptides like dynorphin and enkephalin interact with specific receptors.
• Understanding receptor-ligand interactions is crucial for developing targeted therapeutics.

Purpose of the Study:

• To compare the structural requirements of the dynorphin (kappa) receptor and mu-receptor binding sites.
• To investigate the effects of conformational constraints on dynorphin and enkephalin analogs.

Main Methods:

• Synthesis and testing of dynorphin-(1-13) and [Leu5]enkephalin analogs.
• Guinea pig ileum (GPI) and mouse vas deferens (MVD) bioassays.
• Mu- and delta-opioid receptor binding assays.
• Fluorescence energy transfer (FRET) measurements.

Main Results:

• Dynorphin (kappa) receptor binding domain has distinct structural needs compared to the mu-receptor.
• Identical conformational constraints in both dynorphin and enkephalin analogs yield superpotent agonists.
• Dynorphin-(1-13) analogs exhibit a more extended N-terminal conformation than [Leu5]enkephalin analogs.

Conclusions:

• Kappa and mu opioid receptors possess different structural requirements for enkephalin-like ligands.
• Conformational restriction is a viable strategy for enhancing opioid peptide agonist potency.
• Dynorphin-(1-17) lacks N- and C-terminal segment interaction, suggesting a more extended structure.